2C Tech Company Overview
2C Tech is leveraging unique expertise in nanoparticle technologies for the creation of innovative therapeutic approaches for the treatment of ophthalmic diseases and conditions. The Company’s immediate focus is on the development of a proprietary therapy for patients with retinal degenerative conditions, for whom no effective treatment is currently available. While initially focused on Retinitis Pigmentosa (RP), the 2C Tech approach could also have positive benefits in certain forms of Macular Degeneration, Glaucoma and Diabetic Retinopathy, where patient populations are far greater.
There is a worldwide growing epidemic of blindness from age-related eye diseases; 40 million suffering from Macular Degeneration/RP and 46 million suffering from Diabetic Retinopathy. In the area of Macular Degeneration/RP, there has been a 14% progress to blindness in 5 years, 35% of all blindness, including 2 million RP patients. Diabetic Retinopathy is growing 6% per year, with 1.7 million of the patients with severe disease.
2C Tech (Irvine, CA) has been developing a Quantum Dot technology with the intention of delivering a photovoltaic stimulation to the retina in patients with retinal degenerative diseases. Quantum dots (QDs) are semiconductor crystalline structures a few nanometers wide which absorb light, and generate a voltaic response that can be visualized as emitted light of only a strictly defined wavelength.
These particles can be introduced into the vitreous of the eye via pars plana injection, migrate by diffusion through the retina, and eventually are excreted out by normal biological processes. While in the layers of the retina, the particle emissions result in direct stimulation of the photoreceptors, and elicit the release of growth factors that may amplify or extend the duration of effect. The intended result would be a periodically administered treatment that could preserve or enhance vision in patients with these degenerative diseases.
The Company initially conducted pre-clinical studies in appropriate animal models, and has also conducted early feasibility – First in Human study. The animal studies demonstrated clear positive effects in photoreceptor survival, ERG (electrical response), and visual performance. In the human testing, the ability to safely introduce the QDs was demonstrated, and qualitative measures of vision showed significant promise.
2C Tech is currently in discussions with the Center for Devices and Radiological Health (CDRH) at the U.S. Food and Drug Administration (FDA) pursuing the Investigational Device Exemption (IDE) for Early Feasibility Medical Device Clinical Studies. 2C Tech believes early collaboration with the FDA will provide continuity from early clinical use through pivotal studies to approval in the US.
The Company is now raising Series B funding to enable a randomized and controlled clinical trial in patients with mid-stage RP, and will be positioned to conduct a full regulatory clearance trial in the US. Of the targeted funding, half has already been funded by a lead investor, and the Company is now actively executing on the intended strategies and plans.
The Company has a very experienced Management team; committed and knowledgeable investors; and a network of top tier scientific, clinical and industry advisors to help guide and implement the next phase of the development.